Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Anti-Viral Patent Granted in Hong Kong

April 11, 2022

Positive safety data from 4th Cohort -Phase I Clinical Trial

March 29, 2022

$3.08m R&D Rebate Received

March 28, 2022

Safety Committee Clears PhI R327 Dose Increase

March 6, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Positive Safety Continues in 3rd Cohort PhI Clinical Trial

February 20, 2022

Positive Safety Data from Third Cohort of PI Clinical Trial

February 7, 2022

Positive Safety Data from Second Cohort of PI Clinical Trial

January 18, 2022

Positive Safety Data from Phase 1 Clinical Trial

January 6, 2022

Patients to be Dosed in Ph 1 IV Clinical Trial of R327

December 14, 2021

Update on Phase I/II Clinical Trial for Burn Wound Infection

December 6, 2021

Appendix 4C and Activity Report

October 29, 2021

Ethics Approval to Start Phase 1 Intravenous Clinical Trial

October 24, 2021

Reinstatement to Official Quotation

October 12, 2021

Court Orders Granted

October 11, 2021

Suspension from Official Quotation

October 11, 2021

Trading halt

October 8, 2021

R327 Phase I Clinical Trial Registered on ANZCTR

September 30, 2021

Recce Receives Further Innovation Connections Grant

August 11, 2021

Anti-Viral Patent Granted in USA for RECCE Anti-Infectives

July 22, 2021

Anti-Viral Patent Granted in China

July 20, 2021

Outstanding Efficacy Against Flesh-Eating Bacteria

July 19, 2021

Multiple Patients Dosed in Topical Phase I/II Clinical Trial

July 11, 2021

Recce Clinical Pipeline Update

June 7, 2021

R327 Demonstrates World First Multiple Mechanisms of Action

May 27, 2021

R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO

May 19, 2021

Positive Data on RECCE 327 Against All Six ESKAPE Pathogens

May 3, 2021

RECCE 327 Registered for Topical Burns Study in Humans

April 15, 2021

Positive Sinusitis Patient Update - Special Access Scheme

April 7, 2021

Positive Sinusitis Data Against Infection

March 31, 2021

Anti-Viral Patent Granted in EU for RECCE Anti-Infectives

March 30, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange

March 7, 2021

Appendix 4D and Half Yearly Report

February 25, 2021

Recce Applies for Dual Listing on Frankfurt Stock Exchange

February 23, 2021

Fiona Stanley Hospital Phase I/II Clinical Trial Agreement

February 15, 2021

Further Encouraging COVID Results at Doherty

February 11, 2021

R&D Incentive Rebate Received

February 3, 2021

Positive Intranasal Animal Data against SARS-CoV-2 in Study

December 22, 2020

RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding

December 7, 2020

Recce Awarded AusIndustry Advanced Overseas (R&D) Finding

November 25, 2020

Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives

November 22, 2020

Encouraging Results Against SARS-CoV-2 Virus

November 10, 2020

HREC Approval to Start Phase I/II Burns Wound Study

October 15, 2020

Murdoch Childrens Research Institute, R435 Against H.Pylori

September 30, 2020

Recce Completes Capital Raising of $27.95m

September 23, 2020

R327 Phase I Study - Australias CMAX Clinical Facility

September 10, 2020

Positive & Concentration-Dependent Efficacy Against COVID-19

September 8, 2020

Recce Pharmaceuticals Receives Innovation Connections Grant

August 31, 2020

Recce Pharmaceuticals Appoints James Graham as CEO

August 28, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.